Senior Manager
Takeda
15
0
15
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+3 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (15)
Showing 10 of 15 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Jack A Yanovski, M.D.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Shared therapeutic areas:
Robert B Innis, M.D.
National Institute of Mental Health (NIMH)
Shared therapeutic areas:
Carlos A Zarate, M.D.
National Institute of Mental Health (NIMH)
Shared therapeutic areas:
Paolo Bonato, PhD
Spaulding Rehabilitation Hospital
Shared therapeutic areas:
Herbert B Slade, MD
Healthpoint
Shared therapeutic areas:
Mark George, MD
Medical University of South Carolina
Shared therapeutic areas:
Ali MA Ismail, lecturer
Cairo University
Shared therapeutic areas:
Yair bAR-hAIM, PhD
Tel Aviv University
Shared therapeutic areas:
Hagop Youssoufian, MD
Verastem, Inc.
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (15)
Showing 15 of 15 trials
Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer
Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin
Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis
Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin
Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis
Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease
Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori
Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
Phase III Study of Intramuscular TAK-816 in Healthy Infants
All 15 trials loaded